Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.03
- Piotroski Score 3.00
- Grade Neutral
- Symbol (STTK)
- Company Shattuck Labs, Inc.
- Price $1.01
- Changes Percentage (0%)
- Change -$0
- Day Low $0.94
- Day High $1.02
- Year High $11.76
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $12.00
- High Stock Price Target $16.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.93
- Trailing P/E Ratio -3.64
- Forward P/E Ratio -3.64
- P/E Growth -3.64
- Net Income $-87,298,000
Income Statement
Quarterly
Annual
Latest News of STTK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?
Investors are often attracted to unprofitable companies with potential for success like Shattuck Labs. However, its high cash burn rate raises concerns about future financing and shareholder dilution....
By Yahoo! Finance | 4 months ago
